Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion. Wirz et al.
Description
The aim of this study was to find correlates of high antibody titers in COVID-convalescent plasma (CCP) donors and to study the time course of transfused and endogenous antibody titers in COVID-19 patients. Here, we studied plasma samples from 93 CCP donors collected up to 174 days after symptoms ended. These CCP donors had mild disease. In addition we collected plasma from 16 severe COVID-19 patients before and after CCP transfusion. We measured anti-SARS-CoV-2 Spike RBD, S1, and N-protein antibodies in all samples using ELISA. In addition, capacity of antibodies to block ACE2-RBD binding was assessed. Viral N-protein and viral RNA were measured in plasma of the 16 COVID-19 patients as an estimate for their viral load. The uploaded files contain the data used to make all main and supplementary figures. The file title indicates to which figure the data corresponds to.
Files
Steps to reproduce
Detailed methods are described in Wirz OF, Röltgen K, Stevens BA, Pandey S, Sahoo MK, Tolentino L, Verghese M, Nguyen K, Hunter M, Snow TT, Singh AR, Blish CA, Cochran JR, Zehnder JL, Nadeau KC, Pinsky BA, Pham TD and Boyd SD (2021) Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion. Front. Immunol. 12:739037. doi: 10.3389/fimmu.2021.739037.